Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Not enough attention paid to bone health in prostate cancer

Simon Crabb • 29 Nov 2018
ESMO 2018
Genitourinary Cancer Prostate Cancer Abiraterone Denosumab Radium-223
ERA 223

Skeletal immobility is identified as a significant problem in prostate cancer patients by Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, at the European Society for Medical Oncology (ESMO) 2018 Congress, held in Munich, Germany. Dr Crabb reflects on the data from a recent trial investigating the combination of abiraterone and radium-223 in prostate cancer patients, highlighting the vital need to pay more attention to bone health, and to determine how best patients should be assessed and monitored.

More from Simon Crabb

Prolonging the effects of CBT on managing hot flushes in men with prostate cancer receiving ADT
0:51
Prolonging the effects of CBT on managing hot flushes in men with prostate cancer receiving ADT
Simon Crabb • 6 Jun 2024
How CBT can help manage hot flushes in men with prostate cancer receiving ADT
0:47
How CBT can help manage hot flushes in men with prostate cancer receiving ADT
Simon Crabb • 6 Jun 2024
GUSTO: use of gene expression patterns to identify unique molecular subtypes in MIBC
1:44
GUSTO: use of gene expression patterns to identify unique molecular subtypes in MIBC
Simon Crabb • 1 Jun 2024
Short-term benefits of self-help CBT for managing hot flushes in prostate cancer patients on ADT
1:13
Short-term benefits of self-help CBT for managing hot flushes in prostate cancer patients on ADT
Simon Crabb • 1 Jun 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals